 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
13 News |  |
- || IONIS-GCGRRx / Ionis
P2 data, Journal, Monotherapy: The efficacy and safety of ISIS 449884 injection as monotherapy in patients with type 2 diabetes: A randomized phase II study. (Pubmed Central) - Aug 19, 2024
No abstract available
- || IONIS-GCGRRx / Ionis
Clinical, P2 data, Journal: ISIS 449884 Injection Add-On to Metformin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Study. (Pubmed Central) - Jul 15, 2024
No abstract available The ISIS 449884 injection add-on to metformin significantly reduced HbA1c in patients with T2DM uncontrolled by stable metformin monotherapy and showed an acceptable benefit/risk profile.
- || IONIS-GCGRRx / Ionis
Trial primary completion date: Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 19, 2016
P2, N=80, Active, not recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
The ISIS 449884 injection add-on to metformin significantly reduced HbA1c in patients with T2DM uncontrolled by stable metformin monotherapy and showed an acceptable benefit/risk profile. Trial primary completion date: Sep 2016 --> Dec 2016
- | IONIS-GCGRRx / Ionis
Enrollment closed: Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes (clinicaltrials.gov) - Oct 18, 2016
P2a, N=15, Active, not recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Trial primary completion date: Sep 2016 --> Dec 2016 Recruiting --> Active, not recruiting
- IONIS-GCGRRx / Ionis
New P2a trial: Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes (clinicaltrials.gov) - Jul 6, 2016
P2a, N=15, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
- IONIS-GCGRRx / Ionis
Enrollment closed: Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes (clinicaltrials.gov) - Jul 5, 2016
P2, N=80, Active, not recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| IONIS-GCGRRx / Ionis
New P2 trial: Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 22, 2015
P2, N=80, Recruiting, Sponsor: Isis Pharmaceuticals
- |||| IONIS-GCGRRx / Ionis
Trial completion, Trial primary completion date: Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes (clinicaltrials.gov) - Nov 25, 2014
P2, N=77, Completed, Sponsor: Isis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> May 2014
- ||| IONIS-GCGRRx / Ionis
Enrollment closed: Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes (clinicaltrials.gov) - Nov 11, 2013
P2, N=72, Active, not recruiting, Sponsor: Isis Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> May 2014 Recruiting --> Active, not recruiting
- ||||| IONIS-GCGRRx / Ionis
New P2 trial: Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes (clinicaltrials.gov) - Jun 20, 2013
P2, N=72, Active, not recruiting, Sponsor: Isis Pharmaceuticals